Oriola-KD and MSD renew their long-term cooperation agreement in Finland

Oriola-KD Corporation Stock Exchange Release 17 September 2015 at 10 a.m.

Oriola-KD and MSD renew their long-term cooperation agreement in Finland

Oriola-KD and MSD BV, MSD's Dutch subsidiary and primary supplier for the Nordic
region, have signed a new long-term cooperation agreement on 17 September 2015.
According to the cooperation agreement, Oriola-KD offers MSD pharmaceutical
storage and distribution services and a broad range of tailored services in
Finland.

MSD develops new and innovative pharmaceuticals. In Finland, it focuses on
diabetes, immunology, oncology, infectious diseases, cardiovascular diseases and
central nervous system disorders. MSD invests heavily in pharmaceutical
research. In 2006-2014 MSD's investments in pharmaceutical research in Finland
were approximately EUR 10 million annually and included more than 17,000
patients. The sales of MSD's pharmaceuticals at wholesale prices was EUR 136
million in Finland in 2014 (source: IMS Health).



Oriola-KD Corporation



Eero Hautaniemi
President and CEO


For further information, please contact:

Eero Hautaniemi
President and CEO
tel. +358 10 429 2109
eero.hautaniemi@oriola-kd.com

Distribution:
NASDAQ OMX Helsinki Ltd.
Key media


Released by:
Oriola-KD Corporation
Corporate Communications
Orionintie 5
FI-02200 Espoo
www.oriola-kd.com





[HUG#1952636]